Oral Verapamil in Acute Paroxysmal Supra Ventricular Tachycardia(PSVT) Recurrence Control

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01655316

Enrollment

Registered

2012-08-01

Start date

2010-10-31

Completion date

2011-08-31

Last updated

2012-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paroxysmal Supraventricular Tachycardia

Brief summary

PSVT is a common rhythm disorder in emergency department which can be recurrent in some cases. Intravenous Adenosine is the drug of choice in PSVT control in acute settings but is a very short acting agent. Providing a complementary medication to decrease the rate of recurrence of PSVT after its initial control will be promising. This study evaluates the role of the oral Verapamil in recurrence control of PSVT in emergency situations.

Interventions

DRUGVerapamil

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age\>18 years old * PSVT on emergency department presentation

Exclusion criteria

* Instability in hemodynamic status * Allergy to Verapamil

Design outcomes

Primary

Measure	Time frame
Recurrence Control	2 hours

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026